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Abstract Bloom’s syndrome (BS) is an autosomal recessive
disease, caused by mutations in the BLM gene. This gene
codes for BLM protein, which is a helicase involved in
DNA repair. DNA repair is especially important for the devel-
opment and maturation of the T and B cells. Since BLM is
involved in DNA repair, we aimed to study if BLM deficiency
affects T and B cell development and especially somatic
hypermutation (SHM) and class switch recombination
(CSR) processes. Clinical data of six BS patients was collect-
ed, and immunoglobulin serum levels were measured at dif-
ferent time points. In addition, we performed immune pheno-
typing of the B and T cells and analyzed the SHM and CSR in
detail by analyzing IGHA and IGHG transcripts using next-
generation sequencing. The serum immunoglobulin levels
were relatively low, and patients had an increased number of
infections. The absolute number of T, B, and NK cells were
low but still in the normal range. Remarkably, all BS patients
studied had a high percentage (20–80%) of CD4+ and CD8+
effector memory T cells. The process of SHM seems normal;
however, the Ig subclass distributionwas not normal, since the
BS patients had more IGHG1 and IGHG3 transcripts. In con-
clusion, BS patients have low number of lymphocytes, but the
immunodeficiency seems relatively mild since they have no
severe or opportunistic infections. Most changes in the B cell
development were seen in the CSR process; however, further
studies are necessary to elucidate the exact role of BLM in
CSR.
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Introduction
Bloom’s syndrome (BS) is an autosomal recessive disease,
caused by mutations in the BLM gene located at 15q26. This
gene codes for BLM protein, which is a DNA helicase in-
volved in DNA replication and repair. BS is characterized by
predisposition to malignancy, prenatal growth retardation,
gastro-esophageal reflux, café-au-lait spots, characteristic
butterfly-shaped erythema, and immunodeficiency [1, 2].
The immunodeficiency is characterized by low serum immu-
noglobulins and different infections. Otitis media is a very
common infection among BS patients, especially in children.
Also, up to 20% of the BS patients had pneumonia. [1]
However, the pathophysiology behind the immunodeficiency
in BS has not yet been elucidated.
It is known that DNA repair defects can result in immuno-
deficiency since DNA repair is essential for the development of
antigen receptors expressed on B and T lymphocytes. These
antigen receptors are formed by recombination of the variable
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(V), diversity (D), and joining (J) genes on the antigen receptor
loci. During this V(D)J recombination process, DNA double-
strand breaks (DSBs) are introduced near the V, D, and J genes;
the DNA ends are processed and eventually ligated by the non-
homologous end-joining (NHEJ) DNA repair pathway [3].
When T and B cells express a functional antigen receptor, also
called a T cell receptor (TR) and B cell receptor (BCR), they
can migrate to the periphery where they can encounter an anti-
gen [4]. After antigen encounter, B cells can further divaricate
their BCR by introducing somatic hypermutations (SHM) or by
class switch recombination (CSR). SHM increase the affinity of
the BCR for their antigen, and CSR changes the effector func-
tion of the secreted BCR, also called immunoglobulin or anti-
body. Both SHM and CSR rely on DNA repair. SHM is initi-
ated by AID, which deaminates cytosine (C) into uracils (U),
creating a mismatch with the guanine (G) on the complemen-
tary strand [5, 6]. These U:G mismatches can be resolved using
three different pathways: base excision repair (BER), mismatch
repair (MMR), or replication. During BER, the U is removed
and replaced by a random nucleotide by an error-prone poly-
merase, resulting in transition and transversion mutations at
G/C bases [7, 8]. Mutations at A/T bases can occur via the
MMR pathway when multiple bases surrounding the U:G mis-
match are removed and filled by the error-prone polymerase
eta, which introduces errors at A/T pairs specifically at WA/
TWmotifs [9–11]. Finally, if the U:G mismatch is not repaired
before the DNA is replicated, the U will be recognized as a
thymine (T), resulting in a C to T transition mutation. During
CSR, AID introduces U:G mismatches in the switch regions
upstream of the constant genes in the IGH locus [12].
Subsequently, proteins of the BER pathway introduce DNA
DSBs, which can be repaired by NHEJ or by alternative end-
joining (A-EJ) [13–17].
BLM is described to have a role in at least two DNA repair
pathways involved in lymphocyte development: alternative
end-joining and BER [18–20]. In addition, BLM can also
stimulate DNA synthesis by pol eta [21]. So far, there is no
active role discovered for BLM during V(D)J recombination
[22]. In mice, there is a reduced CSR capacity and a shift to
microhomology-mediated switch junction formation [23].
The aim of this study is to give insight of the immunodefi-
ciency in BS and to discover the role of BLM in CSR and
SHM in humans.
Methods
Cell Samples and Flow Cytometric Immunophenotyping
Peripheral blood samples and clinical data were collected from
six patients with BSwith informed consent and according to the
guidelines of the Medical Ethics Committee of the Radboud
University Nijmegen medical Center and Erasmus MC
Rotterdam. Flow cytometric analysis of peripheral blood for
the healthy controls and patient 5 was performed using 6-
color labeling as previously described [24]. For patient 1–4
and patient 6, an 8-color protocol was used with the following
antibodies: CD24-PB (SN3) (Exbio, Vestec, Czech Republic),
CD45-PO (HI30) (Invitrogen), IgD-FITC and IgM-PE
(Southern Biotechnologies, Birmingham, AL), IgA FITC (IS1
1-8E10) (Mitenyl Biotech, Bergisch Gladbach, Germany), IgD-
biotine (IA6-2) (Biolegend, San Diego, CA), CD45RO-FITC
(UCHL1) (DAKO, Agilent Technologies, Glostrup, Denmark),
CCR7-PE (Miltenyi Biotech), CD28-PE-Cy7 (CD28.2; e-
Bioscience), CD19-PerCP-Cy5 (SJ25C1), CD27-ApC
(LL128), CD38-APC-H7 (HB7), IgG-PE (G18-145), CD4-
PB (RPA-T4), CD3-PerCP (SK7), and CD8-APC-H7 (SK1)
(all from BD Biosciences, CA, USA). The absolute numbers
were calculated BD Trucount™ tubes (BD Bioscience). The
following CD19+ B cell subsets were defined: transitional B
cells as CD24highCD38highCD27−IgM+IgD+, naïve mature B
cells as CD27− CD24dimCD38dimIgM+IgD+, natural effector
B cells as CD27+IgD+CD24dimCD38dim, and memory B cells
as CD27+ IgD−CD24dimCD38dim. The following CD3+ T cell
s ubse t s we r e de f i ned : CD8+ na ïve T ce l l s a s
CD8+CD45RO−CCR7+CD27+CD28+, CD8+ central memory
T cells as CD8+CD45RO+CCR7+CD27+CD28+, CD8+ effec-
tor memory T cells as CD8+CCR7−. CD4+ naïve T cells as
CD8−CD45RO−CCR7+CD27+CD28+, CD4+ central memory
T cells as CD8−CD45RO+CCR7+CD27+CD28+, and CD4+
effector memory T cells as CD8−CCR7−.
Repertoire Analysis of IGH Transcripts Using
Next-Generation Sequencing
PBMC’s were isolated from peripheral blood or cord blood
samples using Ficoll. mRNA was isolated using the Gen-
Elute Mammalian total RNA miniprep kit from Sigma-
Aldrich (St. Louis, MO). cDNAwas created from 2 μg RNA
using the Superscript II reverse transcriptase kit from Invitrogen
(Paisley, UK). IGH rearrangements were amplified in a multi-
plex PCR using the forward VH1-6 FR1 (BIOMED-2) primers
[25] and either the CgCH1 [26] or the IGHA [27] reverse prim-
er. The PCR products were purified and sequenced using Roche
454 sequencing as previously described [28]. In short, PCR
products were purified by gel extraction (Qiagen, Valencia,
CA) and Agencourt AMPure XP beads (Beckman Coulter,
Fullerton, CA). Subsequently, the PCR concentration was mea-
sured using the Quant-it Picogreen dsDNA assay (Invitrogen,
Carlsbad, CA). The purified PCR products were sequenced on
the 454 GS junior instrument according the manufacturer’s rec-
ommendations. Sequences were demultiplexed based on their
multiplex identifier sequence and 40 nucleotides trimmed from
both sides to remove the primer sequence using ARGalaxy
[29] (https://bioinf-galaxian.erasmusmc.nl/argalaxy). Fasta
files were uploaded in IMGT/High-V-Quest [30], and
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subsequently the IMGT output files were analyzed in
ARGalaxy [29]. Only productive sequences that were
complete, without ambiguous bases, present twice or more, in
which a C subclass could be defined, were included once in the
analysis. All information on the FR1 region was excluded from
the analysis since the forward primers used to amplify the
transcripts were located in FR1. The age and number of
sequences used for the analysis are listed in Supplemental
Table 1. The percentage SHM was calculated per sequence by
dividing the number of mutations in the CDR1-FR3 region by
the number of nucleotides in the CDR1-FR3 region. The CDR3
region was excluded from the SHM analysis since it is not
possible to distinguish true somatic mutations from N-nucleo-
tides. In addition, the Immunoglobulin analysis tool (IgAT) [31]
was used to determine the percentage of antigen-selected se-
quences. The data from P1 to P3 were compared to data obtain-
ed from six healthy children (7–15 years) and data from P4 to
P6 were compared to ten healthy adults (31–55 years).
Characterization of Switch Recombination Junctions
The Sμ-Sα recombination fragments were PCR amplified
from DNA derived from peripheral blood cells and sequenced
as previously described [16, 32]. The pattern of CSR junctions
was analyzed according to guidelines [33].
Principal Component Analysis
Z-scores were calculated by the sample score minus the mean
of the controls divided by the standard deviation of the controls.
Thereby, the mean and standard deviation of either the controls
between 7 and 15 years of age (n = 6) or the adult controls
(n = 10) were used. Since we had missing data for either
IGHG or IGHA in three controls, we did not plot these controls
in the graph. This resulted in 32 parameters for 13 controls and
6 BS patients. Subsequently, components and contributions
were calculated and plotted using prcomp in R [34].
Results
Patients
Patient characteristics are shown in Table 1. We describe three
children (9–12 years) and three adult BS patients (36–
49 years). The adult BS patient P4 (SuS or SuSc), P5 (MP
Table 1 Patient characteristics
Patient Age at
analysis
Mutation Birth
weight
Birth
length
Butterfly-
shaped
erythema
Recurrent
ENT
infections
Infections Malignancy Other
P1 9 c.2695C>T/c.2695C>T 1845 Unknown + + Tonsillitis – –
P2 12 c.1933C>T/c.2407-1G>T 2000 45 + + Herpes Zoster
Urinary tract
Respiratory
tract
Gastro-enteritis
Pneumonia
Conjunctivitis
Rhinitis
Paronychia
– –
P3 12 c.1933C>T/c.1933C>T 1025 34 + Neonatal
toxoplasmo-
sis
Growth hormone
replacement therapy
P4 35 c.1284G>A/c.1933C>T 1270 39 + + Pneumonia Squamous cell
carcinoma and
colon
carcinoma
–
P5 37 c.2488_
2489dupA/c.3681del
2000 Unknown + + Bronchitis
Gastro-enteritis
Varicella zoster
Urinary tract
Uveitis
Bacterial
conjunctivas
Polyps
Mamma
carcinoma
Adenocarcinoma
of the bowel
Monoclonal
gammopathy of
unknown
significance
(MGUS)
Diabetes Mellitus
P6 46 c.1933c>T/c.1933c>T 1810 48 ? + Bronchitis Polyp during
colonoscopy
Tonsillectomy
Adenotomy
Abscesses
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or MaPa), and P6 (GC) have been described previously when
they were in their childhood [35, 36]. All patients have a low
birth weight, and birth length indicating a growth deficiency.
The characteristic butterfly-shaped erythema was present in
all patients. Recurrent ear infections were present, which is a
well-known phenomenon in BS [1]. Two adult patients had a
double solid malignancy, both were treated with success.
Patient 5 was diagnosed with a monoclonal gammopathy of
unknown significance (MGUS), which did not deteriorate in a
multiple myeloma so far. In addition, patients suffered from
different infections like bronchitis, uveitis, and two out of five
patients had pneumonia. However, the patients in this cohort
did not have opportunistic infections, sepsis or other life-
threatening manifestations, or a serious failure of the immune
system.
BS Patients Have Subnormal Numbers of Lymphocytes
To elucidate the effect of BLM deficiency on the lymphocyte
development, we analyzed the lymphocyte subsets using flow
cytometry. We compared the absolute numbers of CD3+ T
cells, CD4+ T cells, CD8+ T cells, B cells, and NK cells with
previously published data from 71 healthy children (5–
16 years of age) and 22 healthy adults [37]. The absolute
numbers of B- and NK cells in the BS patients were in the
range of the healthy controls (HC) (Fig. 1a). The absolute
number of T cells was significantly lower in the BS children
compared to HC, and low in the adult BS patients (Fig. 1b).
The CD4+ T cells were significantly reduced in all BS pa-
tients, while the CD8+ T cells were low but in the normal
range. The absolute number of CD4+ and CD8+ naïve, effec-
tor memory (Tem), and central memory (Tcm) populations
were reduced compared to the HC (Fig. 1c). However, the
distribution of the naïve, Tem, and Tcm populations was rel-
atively normal in most of the BS patients, except for P4 who
had a strong decrease in CD4+ and CD8+ naïve T cells
(Fig. 1c). Together, these data showed that BS patients had
subnormal levels of T cells.
Decreased Memory B Cells and Subnormal Levels
of Immunoglobulins
While the total number of B cells were in the normal range,
the absolute number of transitional and naïve mature B cells
was normal or slightly increased, and natural effector B cells
and memory B cells decreased compared to HC (Fig. 2a).
Since this suggests that B cell maturation might be impaired
in the final stages of differentiation, we analyzed the levels
of serum immunoglobulins over the past decades (0–
40 years of age). The IgM, IgG, and IgA levels were all
low but mostly at the border of the normal range during
the years (Fig. 2b). Only P5 has a relative peak in both
IgG, IgM, and IgA at 31 years of age, which is unexplained
so far (Fig. 2b) The low concentration of total IgG was not
caused by a decrease in one of the IgG subclasses, since all
the serum IgG subclasses were at the lower border of the
normal range (Supplemental Fig. 1).
Frequency and Repair of SHM Is Normal in the BS
Patients
Since BLM is involved in BER and has been described to
stimulate DNA syntheses by pol eta, we analyzed the frequency
and repair patterns of SHM in switched B cells. We used next-
generation sequencing to sequence IGHG and IGHA transcripts
from the six BS patients and compared the data to age-matched
controls (see Supplemental Table 1 for overview for the number
of sequences used for the analysis). The median frequency of
SHM in both IGHG and IGHA transcripts was in the normal
range of the age-matched healthy controls (Fig. 3a).
Subsequently, we studied the location and repair patterns of
the SHM, which provide information about the repair pathway
that is used to introduce the mutation during SHM. Similar to
the healthy controls, around 35% of the SHM were located in
RGWY/WRCY (AID) and around 20% in WA/TW (pol eta)
motif, indicating that the targeting of SHM is not aberrant in the
BS patients. Then we investigated the repair patterns of the
SHM in more detail. U:G mismatched resolved by the MMR
pathways lead to mutations at A/T location, and BER is the
dominant pathway for transversion mutations at G/C locations.
In the BS patients, 39–47% of the mutations were located in
A/T locations, which is comparable to the HC. Moreover, the
percentages of transitions and transversions at G/C location in
the BS patients were also within the normal range. This indi-
cated that the targeting and repair mechanisms in SHM are not
affected by the BLM deficiency.
Class Switching to more DownstreamConstant Regions Is
Reduced in BS
Besides V(D)J recombination and SHM, DNA repair is also
crucially important for CSR. We determined the percentages
of rearrangements having a certain Cg or Ca constant gene.
For both children and adult BS patients, the frequency of
IGHG transcripts with Cg1 and Cg3 constant genes were in-
creased compared to age-matched controls. These data sug-
gests that switching to the downstream Cg2 and Cg4 constant
genes is reduced in the BS patients. The frequency of Ca1 and
Ca2 constant genes was normal in the BS children, but the
adults have a slightly higher frequency of Ca2 (Fig. 4).
Since these data indicated that CSR might be hampered in
BS patients, we analyzed the repair of the switch junction to
determine if BLM has a role in CSR. During CSR, AID de-
aminates multiple cytosines in the switch regions upstream of
the constant genes. Since the switch regions contain many
repeats, the DSBs are often repaired using small homologous
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region (microhomology). The BS patients had a significant
increase of 7–9 microhomology in the switch junction; how-
ever, the average microhomology use was not different in the
BS patients we analyzed (Table 2).
Selection of the BCR Repertoire Is Subnormal in BS
Patients
Previous studies have shown that the antigen-experienced B
cells have shorter CDR3 length and express less often a rear-
rangement with the IGHV4-34 gene compared to naïve B cells
[38, 39]. Similar to HC, the CDR3 length was shorter and the
IGHV4-34 usage was reduced in the IGHG and IGHA tran-
scripts derived from the BS patients compared to IGH rear-
rangements derived from naïve B cells from HC (Fig. 5a and
b). In addition, to these changes, BCR rearrangements from
antigen-experienced B cells are selected for replacement mu-
tations in the CDR3 region, since they can increase the affinity
for their antigen, and against replacement mutations in the FR
regions since they can negatively influence the stability of the
antibody protein. Therefore, we compared the replacement/
silent (R/S) mutation ratio in the IGHG and IGHA transcripts
of the BS patients with healthy controls. The R/S ratio seemed
lower in the IGHG transcripts but in the normal range in the
Fig. 1 T cell subsets in BS patients. The absolute numbers of CD19+ B
and CD16+CD56+ NK cells (A), CD3+ T cells, CD4+ T (CD3+ CD8-)
cells, and CD8+ T cells (CD3+ CD8+) (B) are low in the BS patients
compared to the healthy controls (HC). [37] The absolute numbers of
CD4+ and CD8+ naïve (CD45RO−CCR7+CD27+CD28+), central
memory (Tcm) (CD45RO+CCR7+CD27+CD28+), and effector memory
(Tem) (CCR7−) are reduced in the BS patients, but the relative
distribution is normal in most BS patients (C). Significant values were
calculated using the two-tailed Mann-Whitney test and are indicated:
*P ≤ 0.05; **P ≤ 0.01
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IGHA transcripts (Fig. 5c). Additionally, we also used the
Immunoglobulin Analysis tool (IgAT) which calculates for
each rearrangement whether it has undergone antigen selec-
tion based on the number of replacement mutations in relation
to the total number of mutations. The BS patients had a lower
frequency of antigen-selected sequences compared to the age-
matched controls, which was significant in the adult BS pa-
tients (Fig. 5d). These data suggest that antigenic selection of
the B cells is affected by the BLM deficiency.
BS Patients Cluster Differently from Healthy Controls
The data obtained from the IGHG and IGHA transcripts
showed that BS patients have small changes in the subclass
distribution (Fig. 4) and antigen selection (Fig. 5). To see if the
BS patients deviate from the HC, we performed a principal
component analysis (PCA) on all the data obtained from the
IGHG and IGHG transcripts as displayed in Figs. 3, 4, and 5.
This analysis showed that the HC cluster together and that the
Fig. 2 B cells and serum immunoglobulin levels. The absolute numbers
of transitional (IgD+CD27−CD24++CD38++) and naïve mature B cells
(IgD+CD27−CD24+CD38+) are normal or increased in the BS patients
compared to the age-matched healthy controls (HC), while the natural
effector (IgD+CD27+IgM+) and memory B cells (IgD−CD27+) are
decreased (a). The serum IgM, IgG, and IgA immunoglobulin levels
are persistently low in most of the BS patients. The gray area indicates
the range of the reference values. Significant values were calculated using
the two-tailed Mann-Whitney test and are indicated: *P ≤ 0.05
Fig. 3 SHM frequency and
patterns. Frequency of SHM in
IGHG and IGHA transcripts are
low but in the normal range in the
BS patients (a). The mean
percentage of mutations located
in RGYW/WRCY motives and
TW/WA motives (b), and the
mean percentage of mutations at
A/T or G/C (divided in transitions
and transversions) locations (c) is
normal in BS patients. The error
bars indicate the standard
deviation
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BS patients indeed separate from the HC (Fig. 6a). The con-
tribution of each parameter of principal component 1 (PCA1)
and PCA2 are shown in Fig. 6b. So although we did not find
major differences in the B cell repertoire of the BS patients,
their repertoire characteristics are clearly deviate from HC.
Discussion
Immunodeficiency is one of the characteristics of BS; howev-
er, the immunodeficiency is not well described and the under-
lying mechanism is not clear. A long-term follow-up of two
BS patients showed repeated prolonged middle-ear infections
and upper respiratory tract infections several times per year
from 2 till 14 years of age; after which, the frequency of
infections decreased [40]. In our cohort, two patients suffered
from pneumonia, which is a common infection among BS
patients [1]. However, most other infections were minor and
did react well on antibiotics, and no uncommon infections
were noticed. So, although the infections are not severe, in-
fections are more common in BS patients compared to healthy
controls [1]. Therefore, the question remains what causes this
increased susceptibility for infections in these patients.
The longitudinal data of our cohort showed subnormal levels
of serum immunoglobulin levels, especially for IgG and IgM.
This decrease in serum immunoglobulin levels can either be
explained by an intrinsic B cell defect or by a defect in stimu-
lation of B cells by CD4+ Tcells. In this cohort, the naïve B cell
subsets were in the normal range, but the absolute numbers of
natural effector B cells and memory B cells were significantly
lower than the age-matched controls, which might suggest a
maturation defect. Additionally, the CD4+ T cells were de-
creased. Combined, these two factors might contribute to in-
creased numbers of infections observed in the BS patients.
BLM is involved in DNA repair and may have a role in the
DNA repair-dependent processes during lymphoid develop-
ment. Previous studies have shown that BLM does not have a
role in V(D)J recombination [23, 41, 42], and we also did not
observe differences in V, D, and J gene usage, and the number
of deletions, palindromic (P)-nucleotides, and non-templated
(N)-nucleotides (data not shown). The role of BLM in SHM
has not been studied extensively. A study in a small number of
rearrangements (12 IGHV sequences obtained from two BS
patients) showed normal frequency of SHM and distribution
of transition and transversion mutations in the BS patients
[43]. Based on these results, Sack et al. conclude that de im-
munoglobulin hypermutation is normal in BS and that BLM
plays no significant role in the process of SHM. In this study,
we showed in a large number of rearrangements obtained from
six BS patients low but normal frequency of SHM and normal
SHM patterns. Together, these data suggest that BLM is not
essential for SHM.
Table 2 Characterization of Sμ-Sα junctions
ID 0 bp Insertions 1–3 4–6 7–9 ≥ 10 Total no. of junctions
P1 (9 years) 1 (6%) 3 (18%) 5 (29%) 2 (12%) 5 (29%)* 1 (6%) 17
P2 (12 years) 3 (30%) 1 (10%) 3 (30%) 1 (10%) 2 (20%) 0 (0%) 10
P4 (35 years) 3 (25%) 1 (8%) 2 (17%) 4 (33%) 1 (8%) 1 (8%) 12
P5 (37 years) 2 (12%) 3 (18%) 4 (24%) 1 (6%) 4 (23%) 3 (18%)* 17
P6 (46 years) 2 (13%) 2 (13%) 5 (33%) 1 (7%) 3 (20%) 2 (13%) 15
All BS patients 11 (15%) 10 (14%) 19 (27%) 9 (13%) 15 (21%)§# 7 (10%) 71
Controls (child) 31 (17%) 42 (23%) 36 (20%) 29 (16%) 19 (10%) 26 (14%) 183
Controls (adult) 41 (16%) 56 (22%) 91 (36%) 29 (11%) 25 (10%) 14 (5%) 256
The switch junctions were compared with age-matched controls. P1 and P2 with controls (child) and P4, P5, and P6 with controls (adult). Combined data
from all BS patients was both compared with controls (child)§ and controls (adult)# . Italic numbers are significantly different from the age matched controls
*P < 0.05; §P < 0.05; #P < 0.05
Fig. 4 Subclass distribution of the IGH transcripts. BS patients have relatively more IGHG1 and IGHG3 transcripts compared to age-matched controls
(a). The distribution of the IGHA1 and IGHA2 transcripts is normal (b). The bar graphs of the controls indicate the mean and standard deviation
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Fig. 5 Selection characteristics
of the IGH transcripts. The
median CDR3 length of IGHG
and IGHA transcripts in BS
patients is similar to IGHG and
IGHA transcripts from healthy
controls and significantly shorter
than the CDR3 length of naïve B
cells (a). In the BS patients, the
mean percentage of
rearrangements using VH4-34 is
lower compared to naïve B cells
from HC, similarly to switched B
cells from the HC (b). The
replacement/silent (R/S) ratio in
the CDR3 regions of the VH
genes is lower in the BS patients
(c). The percentage of antigen-
selected sequences as determined
using IgAT is lower in the BS
patients (d). All bar graphs
represent the mean and standard
deviation. The line in the dotplots
represents the median. All
columns were compared to the
control naïve column, and
significant values were calculated
using the two-tailed Mann-
Whitney test and are indicated:
*P ≤ 0.05
Fig. 6 Principal component
analysis on the B cell repertoire
characteristics. Principal
component analysis (PCA) on the
data obtained from the IGHG and
IGHA transcripts including
information on the SHM, subclass
distribution, and antigen selection
(a). Graphs showing how much
each variable contributed to
PCA1 and PCA2
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In mice models, there is no crucial role for BLM in the
mechanism of CSR identified [23]. In this study, we showed
that the memory B cells were low in three of the six BS
patients, and the serum immunoglobulins levels were subnor-
mal. The IGHG transcripts in humans showed particularly
Cg3 and Cg1 gene usage with an increased use of short
microhomology in the switch regions. This suggests that B
cells in BS patients switch less to the more downstream Cg2
and Cg4 constant genes. Switching to these more downstream
constant genes happens during the course of an immune re-
sponse and requires CD4+ T cell stimulation [44, 45]. This
indicates that the process of class switch recombination is
disturbed in BS patients, which can either be caused by the
low CD4+ Tcells or an intrinsic B cell defect. Previous studies
have shown that lymphocytes of Blm-deficient mice and BS
patients (including P4, P5, and P6) have reduced proliferation
capacity, which likely also contribute to reduced switching to
the more downstream constant genes since these processes are
dependent on B cell proliferation [23, 35, 36, 46, 47].
However, the immunodeficiency cannot be fully explained
by an impaired CSR, because IgM is also produced at subnor-
mal level, which is independent of CSR.
T cells in the BS patients were low in absolute numbers and
percentages, for both CD4+ and CD8+. It is most likely that the
process is already disturbed in the thymus since all T cell subsets
are reduced compared to the HC. This suggests a possible role of
BLM in the development of T cells. This was also earlier dem-
onstrated in mice models, where mice with a conditional knock-
out of Blm in the Tcell lineage have severely reduced thymocyte
numbers [46]. The reaction of human Tcells on phytohemagglu-
tinin lymphocyte stimulation is disturbed and also stimulation by
pokeweedmitogen is mostly decreased, which is an indication of
less growth of B and T cells [35, 36]. Our results showed a
relative increase of effector memory T cells compared to naïve
and central memory T cells. So far, we can conclude that there is
a disturbance in the development of T cells, which results in
lower Tcell levels, as is shown in our patient series. This reduced
number of Tcells could explain the low number of immunoglob-
ulins andmemoryB cells, as CD4+Tcells stimulate SHM,CSR,
and B cells to produce immunoglobulins.
Conclusion
We showed BS patients suffer from relatively mild infections,
which might be explained by the subnormal level of T, B, and
NK cells and immunoglobulins. The B cell repertoire data on
SHM, subclass distribution, and antigen selection of the B
cells showed that the BS patients did not have great differ-
ences, but they clearly deviated from HC. Most importantly,
despite the multiple disruptions, the immunodeficiency has a
relatively mild character and functions in the laboratory and
clinically at an acceptable level.
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